NEUROCRINE BIOSCIENCES, INC. (NBIX) Operating margin 2016–2025
NEUROCRINE BIOSCIENCES, INC. (NBIX) operating margin by fiscal year — reported operating income divided by reported revenue.
21.6%FY2025 · since FY2016: -982.5% → 21.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 21.6% | -2.6 pp |
| FY2024 | 24.2% | +10.9 pp |
| FY2023 | 13.3% | -3.4 pp |
| FY2022 | 16.7% | +7.7 pp |
| FY2021 | 9.0% | -6.5 pp |
| FY2020 | 15.6% | +6.4 pp |
| FY2019 | 9.2% | +1.0 pp |
| FY2018 | 8.2% | +89.4 pp |
| FY2017 | -81.3% | +901.2 pp |
| FY2016 | -982.5% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More NBIX financial trends
NBIX RevenueNBIX Net incomeNBIX Net marginNBIX Gross profitNBIX Gross marginNBIX Operating incomeNBIX Operating cash flowNBIX Free cash flowNBIX Capital expendituresNBIX Return on equityNBIX Stock buybacksNBIX Dividends paidNBIX Total assetsNBIX Total liabilitiesNBIX Shareholders’ equityNBIX overview →